Latest Peplin news

01-Feb-10

LEO Pharma's PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition read more

Positive Results for LEO Pharma's Phase III Actinic Keratosis Trials on the Face and Scalp read more

Letter to our CDI Holders read more

Archived 2002

25-11-2002		Peplin Out-Licenses Lead Compound for Non-Melanoma Skin Cancer
25-11-2002		Chairman's Address to 2002 AGM
25-09-2002		Peplin Biotech Completes Successful Rights Issue
13-09-2002		Peplin Releases Full Year Results for FY2002
27-08-2002		US Patent Granted
02-08-2002		Rights Issue Announced
18-07-2002		Patent Coverage Expanded
01-07-2002		First Gram of New Anti-Cancer Drug Shipped